KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Non-Current Assets (2016 - 2025)

Resmed (RMD) has disclosed Non-Current Assets for 16 consecutive years, with $4.7 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets rose 8.81% year-over-year to $4.7 billion, compared with a TTM value of $4.7 billion through Dec 2025, up 8.81%, and an annual FY2025 reading of $4.7 billion, up 3.41% over the prior year.
  • Non-Current Assets was $4.7 billion for Q4 2025 at Resmed, roughly flat from $4.7 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $4.7 billion in Q4 2025 and bottomed at $3.1 billion in Q1 2021.
  • Average Non-Current Assets over 5 years is $4.0 billion, with a median of $4.4 billion recorded in 2023.
  • The sharpest move saw Non-Current Assets soared 580.35% in 2021, then decreased 4.9% in 2024.
  • Year by year, Non-Current Assets stood at $3.2 billion in 2021, then soared by 36.5% to $4.4 billion in 2022, then grew by 4.05% to $4.5 billion in 2023, then dropped by 4.9% to $4.3 billion in 2024, then grew by 8.81% to $4.7 billion in 2025.
  • Business Quant data shows Non-Current Assets for RMD at $4.7 billion in Q4 2025, $4.7 billion in Q3 2025, and $4.7 billion in Q2 2025.